Beta Interferons in Clinically Isolated Syndromes

dc.creatorMelo, Ailton de Souza
dc.creatorRodrigues, Bernardo
dc.creatorBar-Or, Amit
dc.creatorMelo, Ailton de Souza
dc.creatorRodrigues, Bernardo
dc.creatorBar-Or, Amit
dc.date.accessioned2011-12-11T14:09:06Z
dc.date.accessioned2022-10-07T15:00:28Z
dc.date.available2011-12-11T14:09:06Z
dc.date.available2022-10-07T15:00:28Z
dc.date.created2011-12-11T14:09:06Z
dc.date.issued2008
dc.identifier1678-4227
dc.identifierhttp://www.repositorio.ufba.br/ri/handle/ri/4788
dc.identifier66(1)
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/4003845
dc.description.abstractBeta-interferon use in definite multiple sclerosis (MS) has been proven to modify clinical and magnetic resonance imaging outcome. We review and summarize the data of published double-blind, randomized clinical trials to assess, with a meta-analysis the safety and efficacy of beta-interferon on the occurrence of relapses in patients with a first clinical event suggestive of MS. After two years of follow-up, interferon beta decreased the risk of conversion to clinically definite MS 0.51[0.39-0.65], and delayed the time to diagnosis up to 367 days. Side-effects were mild and self limited. Our findings support the efficacy of early treatment with beta-interferon in reducing conversion to clinically defined MS in patients with clinically isolated syndromes.
dc.languageen
dc.subjectinterferon
dc.subjectclinically isolated syndromes
dc.subjectmultiple sclerosis
dc.subjectimmunomodulating therapy
dc.titleBeta Interferons in Clinically Isolated Syndromes
dc.typeArtigo Publicado em Periódico


Este ítem pertenece a la siguiente institución